Did you know?

ChinaBio® Group is a consulting and advisory firm helping life science companies and investors achieve success in China. ChinaBio works with U.S., European and APAC companies and investors seeking partnerships, acquisitions, novel technologies and funding in China.  

Learn more >>

Free Newsletter

Have the latest stories on China's life science industry delivered to your inbox daily or weekly - free!

  Email address:
   

PAG Pays $540 Million for Majority Stake in Hisun BioRay, a Biologics Company

publication date: Sep 6, 2019

Following a bidding war, Hong Kong private equity firm PAG will pay $540 million to acquire a 58% stake in Hisun BioRay, a biologics company with a focus in autoimmune and oncology drugs. It is the largest private equity deal in China biopharma this year, according to the companies. BioRay is the biologics subsidiary of Zhejiang Hisun Pharma, a company that specializes in generic drugs and APIs. BioRay already markets an autoimmune treatment in China and is developing ten other biologics. More details....

Stock Symbols: (SHA: 600267)

Share this with colleagues:


This article is available for purchase - please click here for details.

Sorry this page is available to subscribers only.
If you're not a subscriber why not subscribe today?

If you are already a subscriber, please login.

If you believe you should have received this message in error, please contact us.


 

To gain access to the members only content click here to subscribe.

You will be given immediate access to premium content on the site.

Upcoming event
August 25-27, 2020
China Standard Time
ChinaBio® News

Greg Scott BIO-Europe Interview
Greg Scott Interviewed at BIO-Europe Spring

How to bring your China assets to China in 8 minutes


Greg Scott Mendelspod Interview
"Mr. Bio in China."
Mendelspod Interview

Multinational pharma held to a higher standard in China